SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 19, 2002; DOI 10.1182/blood-2002-06-1793. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-06-1793v1 101/2/391    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cheson, B. D. Search for Related Content PubMed PubMed Citation Articles by Cheson, B. D. Related Collections Review Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 January 2003, Vol. 101, No. 2, pp. 391-398 REVIEW ARTICLE Radioimmunotherapy of non-Hodgkin lymphomas Bruce D. Cheson From the Georgetown University Hospital, Lombardi Cancer Center, Washington, DC. Enthusiasm for the use of monoclonal antibodies, such as rituximab, has markedly changed the approach to patients with non-Hodgkin lymphomas (NHLs). Nevertheless, more effective therapies are needed. Radioimmunotherapy as a form of targeted radiation therapy may add significantly to our therapeutic options. Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and Drug Administration, and iodine I 131 tositumomab have demonstrated a high level of activity in patients whose NHL has failed to respond to chemotherapy and rituximab. Toxicities have primarily included prolonged myelosuppression, with a potential risk of treatment-associated myelodysplastic syndrome and acute myelogenous leukemia. Ongoing clinical trials are attempting to better characterize the role of these promising agents. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. B. Toma and P. J. Medina Update on Targeted Therapy--Focus on Monoclonal Antibodies Journal of Pharmacy Practice, February 1, 2008; 21(1): 4 - 16. [Abstract] [PDF] R. Balhorn, S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman, A. Zemla, G. Mirick, J. Perkins, A. Natarajan, M. Corzett, et al. Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia Clin. Cancer Res., September 15, 2007; 13(18): 5621s - 5628s. [Abstract] [Full Text] [PDF] E. Cooney-Qualter, M. Krailo, A. Angiolillo, R. A. Fawwaz, G. Wiseman, L. Harrison, V. Kohl, P. C. Adamson, J. Ayello, C. vande Ven, et al. A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non Hodgkin's Lymphoma: A Children's Oncology Group Study Clin. Cancer Res., September 15, 2007; 13(18): 5652s - 5660s. [Abstract] [Full Text] [PDF] S. E. Strome, E. A. Sausville, and D. Mann A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects Oncologist, September 1, 2007; 12(9): 1084 - 1095. [Abstract] [Full Text] [PDF] M. N. Lopez, C. Pereda, M. Ramirez, A. Mendoza-Naranjo, A. Serrano, A. Ferreira, R. Poblete, A. M. Kalergis, R. Kiessling, and F. Salazar-Onfray Melanocortin 1 Receptor Is Expressed by Uveal Malignant Melanoma and Can Be Considered a New Target for Diagnosis and Immunotherapy Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1219 - 1227. [Abstract] [Full Text] [PDF] D. M. Goldenberg Adjuvant and Combined Radioimmunotherapy: Problems and Prospects on the Road to Minerva J. Nucl. Med., November 1, 2006; 47(11): 1746 - 1748. [Full Text] [PDF] I. Burvenich, S. Schoonooghe, B. Cornelissen, P. Blanckaert, E. Coene, C. Cuvelier, N. Mertens, and G. Slegers In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131-Labeled Monoclonal Antibody 14C5 in a Non-Small Cell Lung Cancer and Colon Carcinoma Model Clin. Cancer Res., October 15, 2005; 11(20): 7288 - 7296. [Abstract] [Full Text] [PDF] R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies J. Clin. Oncol., September 20, 2005; 23(27): 6719 - 6729. [Abstract] [Full Text] [PDF] R. Schnell, M. Dietlein, J. O. Staak, P. Borchmann, K. Schomaecker, T. Fischer, W. Eschner, H. Hansen, F. Morschhauser, H. Schicha, et al. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody J. Clin. Oncol., July 20, 2005; 23(21): 4669 - 4678. [Abstract] [Full Text] [PDF] H.-M. Cho, J. D. Rosenblatt, Y.-S. Kang, M. L. Iruela-Arispe, S. L. Morrison, M. L. Penichet, Y.-G. Kwon, T.-W. Kim, K. A. Webster, H. Nechustan, et al. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein Mol. Cancer Ther., June 1, 2005; 4(6): 956 - 967. [Abstract] [Full Text] [PDF] J. M. Connors Radioimmunotherapy -- Hot New Treatment for Lymphoma N. Engl. J. Med., February 3, 2005; 352(5): 496 - 498. [Full Text] [PDF] M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF] K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Clin. Cancer Res., October 15, 2004; 10(20): 7063 - 7070. [Abstract] [Full Text] [PDF] B. D. Cheson What Is New in Lymphoma? CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272. [Abstract] [Full Text] [PDF] A. D. Klion, J. Robyn, C. Akin, P. Noel, M. Brown, M. Law, D. D. Metcalfe, C. Dunbar, and T. B. Nutman Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome Blood, January 15, 2004; 103(2): 473 - 478. [Abstract] [Full Text] [PDF] M. J. Ahn, J. S.A. Adamson, and D. Dornbusch From Leaders to Leadership: Managing Change Journal of Leadership and Organizational Studies, January 1, 2004; 10(4): 112 - 123. [Abstract] [PDF] M. Miederer, M. R. McDevitt, G. Sgouros, K. Kramer, N.-K. V. Cheung, and D. A. Scheinberg Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates J. Nucl. Med., January 1, 2004; 45(1): 129 - 137. [Abstract] [Full Text] [PDF] B. Mavromatis and B. D. Cheson Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia J. Clin. Oncol., May 1, 2003; 21(9): 1874 - 1881. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020